The choice for government might be higher prices or access delays

March 13, 2019 Comment

This is a preview of subscriber content

Subscribe now to continue reading.

The irony of proposed changes that will effectively eliminate Special Pricing Arrangements is that they will probably leave government with the choice of paying higher prices or denying patient access. …

Subscribe now to continue reading.

Latest Video

‘Trojan Horse’ treatment offers hope for Australians facing relapsed multiple myeloma
November 24, 2025 - Latest News
New national report warns of deepening ovarian cancer burden and calls for urgent action
November 24, 2025 - Latest News
NSW Premier opens Australia’s first large-scale health translation hub at UNSW
November 24, 2025 - Latest News
Australia has 'all the ingredients' but has to decide what kind of health system it wants
November 26, 2025 - BioPharma
New review recommends a balanced and measured approach to adopting AI in clinical practice
November 24, 2025 - BioPharma

The choice for government might be higher prices or access delays

This is a preview of subscriber content

Latest Video

Most Read

‘Trojan Horse’ treatment offers hope for Australians facing relapsed multiple myeloma

New national report warns of deepening ovarian cancer burden and calls for urgent action

NSW Premier opens Australia’s first large-scale health translation hub at UNSW

Australia has 'all the ingredients' but has to decide what kind of health system it wants

New review recommends a balanced and measured approach to adopting AI in clinical practice

New Stories

Neurizon Therapeutics entering 'a promising new horizon” as ALS program advances

Slade Pharmacy marks anniversary with record research contributions at conferences

US secures significant price reductions on 15 medicines in second round of medicare negotiations

The US and UK edging close to an agreement on pharmaceutical pricing

US Medicare sets reimbursement price for PromarkerD, paving way for major commercial rollout

Recce reports strong preclinical efficacy for inhaled R327 in hospital-acquired pneumonia model

Race Oncology secures human ethics approval for lung cancer trial of RC220

Sign In

The choice for government might be higher prices or access delays

This is a preview of subscriber content

Latest Video

Most Read

‘Trojan Horse’ treatment offers hope for Australians facing relapsed multiple myeloma

New national report warns of deepening ovarian cancer burden and calls for urgent action

NSW Premier opens Australia’s first large-scale health translation hub at UNSW

Australia has 'all the ingredients' but has to decide what kind of health system it wants

New review recommends a balanced and measured approach to adopting AI in clinical practice

Follow Us

New Stories

Neurizon Therapeutics entering 'a promising new horizon” as ALS program advances

Slade Pharmacy marks anniversary with record research contributions at conferences

US secures significant price reductions on 15 medicines in second round of medicare negotiations

The US and UK edging close to an agreement on pharmaceutical pricing

US Medicare sets reimbursement price for PromarkerD, paving way for major commercial rollout

Recce reports strong preclinical efficacy for inhaled R327 in hospital-acquired pneumonia model

Race Oncology secures human ethics approval for lung cancer trial of RC220